The Association Between Helicobacter pylori Infection and Insulin Resistance: A Systematic Review
Stergios A. Polyzos,
Jannis Kountouras,
Christos Zavos,
Georgia Deretzi,
Stergios A. Polyzos
Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia, Greece
Search for more papers by this authorJannis Kountouras
Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia, Greece
Search for more papers by this authorChristos Zavos
Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia, Greece
Search for more papers by this authorGeorgia Deretzi
Department of Neurology, Papageorgiou General Hospital, Thessaloniki, Greece
Search for more papers by this authorStergios A. Polyzos,
Jannis Kountouras,
Christos Zavos,
Georgia Deretzi,
Stergios A. Polyzos
Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia, Greece
Search for more papers by this authorJannis Kountouras
Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia, Greece
Search for more papers by this authorChristos Zavos
Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia, Greece
Search for more papers by this authorGeorgia Deretzi
Department of Neurology, Papageorgiou General Hospital, Thessaloniki, Greece
Search for more papers by this authorReprint requests to: Jannis Kountouras, M.D., Ph.D., Professor of Medicine, Gastroenterologist, Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, 8 Fanariou st., Byzantio, 55133 Thessaloniki, Greece. E-mail: [email protected]
Abstract
Background: Helicobacter pylori infection has been associated with diverse extradigestive morbidity, including insulin resistance (IR) syndrome. The aim of this systematic review was to summarize the epidemiologic evidence concerning the association between H. pylori infection and IR quantitative indexes.
Materials and Methods: A computerized literature search in PubMed electronic databases and Cochrane Central Register of Controlled Trials was performed.
Results: Nine studies reporting data on 2120 participants were finally eligible for this systematic review. Seven of them were cross-sectional studies and two were nonrandomized, open-label, controlled trials investigating the effect of H. pylori eradication on IR. Homeostatic model of assessment insulin resistance (HOMA-IR) was used in all studies to quantify IR. There seems to be a trend toward a positive association between H. pylori infection and HOMA-IR, strengthened by regression analysis in one study. However, there was significant heterogeneity between studies regarding the method(s) of H. pylori infection diagnosis based on and the study populations. The studies for the effect of H. pylori eradication on HOMA-IR revealed conflicting results.
Conclusions: Although data seem to indicate a potential association between H. pylori infection and IR, further studies are needed to strengthen this association and to clarify whether there is a causative link between them. If a causal link is confirmed in the future, this may have a major impact on the pathophysiology and management of IR syndrome, including type 2 diabetes mellitus and nonalcoholic fatty liver disease.
References
- 1 Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009; 72: 299–314.
- 2 Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010; 375: 181–3.
- 3 Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 2010; 53: 600–5.
- 4 Razzouk L, Muntner P. Ethnic, gender, and age-related differences in patients with the metabolic syndrome. Curr Hypertens Rep 2009; 11: 127–32.
- 5 Bruce KD, Hanson MA. The developmental origins, mechanisms, and implications of metabolic syndrome. J Nutr 2010; 140: 648–52.
- 6 Tereshina EV. Metabolic abnormalities as a basis for age-dependent diseases and aging? State of the art. Adv Gerontol 2009; 22: 129–38.
- 7 Gen R, Demir M, Ataseven H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South Med J 2010; 103: 190–6.
- 8 Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am J Gastroenterol 2008; 103: 3005–10.
- 9 Pellicano R, Franceschi F, Saracco G, Fagoonee S, Roccarina D, Gasbarrini A. Helicobacters and extragastric diseases. Helicobacter 2009; 14(Suppl 1): 58–68.
- 10
Alberti KG,
Zimmet PZ.
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.
Diabet Med
1998; 15: 539–53.
10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 11 Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059–62.
- 12 Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442–3.
- 13 Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237–52.
- 14 National Cholesterol Education Program (NCEP) expert panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–421.
- 15 Winchester DE, Bavry AA. Limitations of the MEDLINE Database in Constructing Meta-analyses. Ann Intern Med 2010; 153: 347–8.
- 16 Wilczynski NL, Haynes RB. Robustness of empirical search strategies for clinical content in MEDLINE. Proc AMIA Symp 2002; 5: 904–8.
- 17 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9.
- 18 Aslan M, Horoz M, Nazligul Y, Bolukbas C, Bolukbas FF, Selek S, Celik H, Erel O. Insulin resistance in H. pylori infection and its association with oxidative stress. World J Gastroenterol 2006; 12: 6865–8.
- 19 Aydemir S, Bayraktaroglu T, Sert M, Sokmen C, Atmaca H, Mungan G, Gun BD, Borazan A, Ustundag Y. The effect of Helicobacter pylori on insulin resistance. Dig Dis Sci 2005; 50: 2090–3.
- 20 Eshraghian A, Hashemi SA, Hamidian Jahromi A, Eshraghian H, Masoompour SM, Davarpanah MA, Eshraghian K, Taghavi SA. Helicobacter pylori infection as a risk factor for insulin resistance. Dig Dis Sci 2009; 54: 1966–70.
- 21 Gao XY, Kuang HY, Liu XM, Duan P, Yang Y, Ma ZB. Circulating ghrelin/obestatin ratio in subjects with Helicobacter pylori infection. Nutrition 2009; 25: 506–11.
- 22 Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter 2009; 14: 144–50.
- 23 Ozdem S, Akcam M, Yilmaz A, Artan R. Insulin resistance in children with Helicobacter pylori infection. J Endocrinol Invest 2007; 30: 236–40.
- 24 Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Kim BI, Keum DK. Helicobacter pylori eradication has no effect on metabolic and inflammatory parameters. J Natl Med Assoc 2005; 97: 508–13.
- 25 So WY, Tong PC, Ko GT, Ma RC, Ozaki R, Kong AP, Yang X, Ho CS, Lam CC, Chan JC. Low plasma adiponectin level, white blood cell count and Helicobacter pylori titre independently predict abnormal pancreatic beta-cell function. Diabetes Res Clin Pract 2009; 86: 89–95.
- 26 Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57–63.
- 27 Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487–95.
- 28 Tresaco B, Bueno G, Pineda I, Moreno LA, Garagorri JM, Bueno M. Homeostatic model assessment (HOMA) index cut-off values to identify the metabolic syndrome in children. J Physiol Biochem 2005; 61: 381–8.
- 29 Yavasoglu I, Kucuk M, Cildag B, Arslan E, Gok M, Kafkas S. A novel association between polycystic ovary syndrome and Helicobacter pylori. Am J Med Sci 2009; 338: 174–7.
- 30 Longo-Mbenza B, Nkondi NJ, Vangu ND. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics. Int J Cardiol 2007; 121: 229–38.
- 31 Nabipour I, Vahdat K, Jafari SM, Pazoki R, Sanjdideh Z. The association of metabolic syndrome and Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex virus type 1: the Persian Gulf Healthy Heart Study. Cardiovasc Diabetol 2006; 5: 25.
- 32 Gillum RF. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the Third National Health and Nutrition Examination Survey. J Natl Med Assoc 2004; 96: 1470–6.
- 33 Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ 1998; 316: 1130–2.
- 34 Sotiropoulos A, Gikas A, Skourtis S, Merkouris P, Pentzeridis P, Polydorou A, Pappas S. Seropositivity to Chlamydia pneumoniae or Helicobacter pylori and coronary artery disease. Int J Cardiol 2006; 109: 420–1.
- 35 Ciortescu I, Sfarti C, Stan M, Graur M, Stanciu C. Prevalence of Helicobacter pylori infection in patients with diabetes mellitus. Rev Med Chir Soc Med Nat Iasi 2009; 113: 1048–55.
- 36 Grundy SM. Does the metabolic syndrome exist? Diabetes Care 2006; 29: 1689–92.
- 37 Davidson MB. Does the metabolic syndrome exist: response to Grundy. Diabetes Care 2006; 29: 2565–6.
- 38 Ricci C, Holton J, Vaira D. Diagnosis of Helicobacter pylori: invasive and non-invasive tests. Best Pract Res Clin Gastroenterol 2007; 21: 299–313.
- 39 Eshraghian A. The continuous story of Helicobacter pylori infection and insulin resistance: this time in Japan. Helicobacter 2010; 15: 160.
- 40 Imai J, Yamada T, Saito T, Ishigaki Y, Hinokio Y, Kotake H, Oka Y, Katagiri H. Eradication of insulin resistance. Lancet 2009; 374: 264.
- 41 Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772–81.
- 42 Cicconi V, Carloni E, Franceschi F, Nocente R, Silveri NG, Manna R, Servidei S, Bentivoglio AR, Gasbarrini A, Gasbarrini G. Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication. Am J Med 2001; 111: 163–4.
- 43 Zentilin P, Seriolo B, Dulbecco P, Caratto E, Iiritano E, Fasciolo D, Bilardi C, Mansi C, Testa E, Savarino V. Eradication of Helicobacter pylori may reduce disease severity in rheumatoid arthritis. Aliment Pharmacol Ther 2002; 16: 1291–9.
- 44 Gupta V, Eden AJ, Mills MJ. Helicobacter pylori and autoimmune neutropenia. Clin Lab Haematol 2002; 24: 183–5.
- 45 Cindoruk M, Cirak MY, Unal S, Karakan T, Erkan G, Engin D, Dumlu S, Turet S. Identification of Helicobacter species by 16S rDNA PCR and sequence analysis in human liver samples from patients with various etiologies of benign liver diseases. Eur J Gastroenterol Hepatol 2008; 20: 33–6.
- 46 Pirouz T, Zounubi L, Keivani H, Rakhshani N, Hormazdi M. Detection of Helicobacter pylori in paraffin-embedded specimens from patients with chronic liver diseases, using the amplification method. Dig Dis Sci 2009; 54: 1456–9.
- 47 Basso D, Plebani M, Kusters JG. Pathogenesis of Helicobacter pylori infection. Helicobacter 2010; 15(Suppl 1): 14–20.
- 48 Aebischer T, Meyer TF, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter. Helicobacter 2010; 15(Suppl 1): 21–8.
- 49 Yeh JJ, Tsai S, Wu DC, Wu JY, Liu TC, Chen A. P-selectin-dependent platelet aggregation and apoptosis may explain the decrease in platelet count during Helicobacter pylori infection. Blood 2010; 115: 4247–53.
- 50 Restituto P, Colina I, Varo JJ, Varo N. Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome. Am J Physiol Endocrinol Metab 2010; 298: 1072–7.
- 51 Evrengul H, Tanriverdi H, Kuru O, Enli Y, Yuksel D, Kilic A, Kaftan A, Kirac S, Kilic M. Elevated homocysteine levels in patients with slow coronary flow: relationship with Helicobacter pylori infection. Helicobacter 2007; 12: 298–305.
- 52 Hsieh MJ, Chen CC, Lee TH, Lee CH, Wen MS, Lin FC, Hsieh IC, Wu D. Metabolic syndrome and homocysteine level as predictors of the severity of coronary artery disease in patients with carotid stenosis. Am J Med Sci 2009; 338: 447–52.
- 53 Osawa H, Nakazato M, Date Y, Kita H, Ohnishi H, Ueno H, Shiiya T, Satoh K, Ishino Y, Sugano K. Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. J Clin Endocrinol Metab 2005; 90: 10–6.
- 54 Pöykkö SM, Kellokoski E, Hörkkö S, Kauma H, Kesäniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003; 52: 2546–53.
- 55 Roper J, Francois F, Shue PL, Mourad MS, Pei Z, Olivares de Perez AZ, Perez-Perez GI, Tseng CH, Blaser MJ. Leptin and ghrelin in relation to Helicobacter pylori status in adult males. J Clin Endocrinol Metab 2008; 93: 2350–7.
- 56 Polyzos SA, Kountouras J, Zavos C, Deretzi G. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J Clin Gastroenterol 2011; 45: 50–4.
- 57 Arrese M, Riquelme A, Soza A. Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications. Ann Hepatol 2010; 9(Suppl): 112–8.
- 58 Persico M, Masarone M, La Mura V, Persico E, Moschella F, Svelto M, Bruno S, Torella R. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. World J Gastroenterol 2009; 15: 462–6.
- 59 El-Masry S, El-Shahat M, Badra G, Aboel-Nour MF, Lotfy M. Helicobacter pylori and Hepatitis C Virus Coinfection in Egyptian Patients. J Glob Infect Dis 2010; 2: 4–9.
- 60 Kumar M, Choudhury A, Manglik N, Hissar S, Rastogi A, Sakhuja P, Sarin SK. Insulin resistance in chronic hepatitis B virus infection. Am J Gastroenterol 2009; 104: 76–82.
- 61 Bevilacqua M, Dominguez LJ, Barbagallo M. Insulin Resistance and the cardiometabolic syndrome in HIV infection. J Cardiometab Syndr 2009; 4: 40–3.
- 62 Ebrahimi A, Nabipour I, Vahdat K, Jafari SM, Fouladvand M, Assadi M, Movahed A, Obeidi N, Sanjdideh Z. High sensitivity C-reactive protein is associated with the metabolic syndrome independent to viral and bacterial pathogen burden. Diabetes Res Clin Pract 2009; 84: 296–302.
- 63 Fernández-Real JM, López-Bermejo A, Vendrell J, Ferri MJ, Recasens M, Ricart W. Burden of infection and insulin resistance in healthy middle-aged men. Diabetes Care 2006; 29: 1058–64.
- 64 Fernández-Real JM, Ferri MJ, Vendrell J, Ricart W. Burden of infection and fat mass in healthy middle-aged men. Obesity (Silver Spring) 2007; 15: 245–52.
- 65 Rowland M, Daly L, Vaughan M, Higgins A, Bourke B, Drumm B. Age-specific incidence of Helicobacter pylori. Gastroenterology 2006; 130: 65–72.
